Q-omics provides the consensus-scored MIS18A profile across patient tissues and cancer cell-line models. MIS18A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIS18A is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, MIS18A RNA expression shows 21,571 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where MIS18A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIS18A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIS18A survival associations across molecular data types. MIS18A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIS18A RNA expression–survival associations across cancer types. High MIS18A expression shows unfavorable associations in ACC, KIRP, MESO, LGG, KICH and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIS18A RNA expression.
This table summarizes MIS18A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MIS18A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIS18A shows higher tumor expression in BLCA, HNSC, COAD, LUAD, LIHC and STAD. The BLCA box plot shows higher MIS18A RNA expression in tumor versus normal tissue (log2 FC = +2.035, t-test p < 0.001).
This table shows molecular features associated with MIS18A in patient tissues and cancer cell lines. In patient samples, MIS18A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MIS18A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
